Morphological restructuring of myocardium during the early phase of experimental diabetes mellitus

Anatomical Record

Volumn 298, Issue 2, 2015, Pages 396-407

  Danilova, I G ^a,b   Sarapultsev, P A ^a   Medvedeva, S U ^a,b   Gette, I F ^a   Bulavintceva, T S ^a   Sarapultsev, A P ^a  

^a INSTITUTE OF IMMUNOLOGY AND PHYSIOLOGY   (Russian Federation)

^b URAL FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Alloxan; Early stage; Experimental diabetes; Right auricle

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN;

ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRIFUGATION; CHEMICAL ANALYSIS; EPICARDIUM; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART MUSCLE; HEART MUSCLE CELL; INSULIN DEPENDENT DIABETES MELLITUS; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; ANIMAL; BLOOD; MALE; METABOLISM; MICROCIRCULATION; PATHOLOGY; PHYSIOLOGY;

ANIMALIA; RATTUS;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICROCIRCULATION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS;

EID: 84920973455     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.23052     Document Type: Article

References (93)

1. Abraham AS, Kay JM, Cole RB, Pincock AC. 1971. Hemodynamic and pathological study of the effect of chronic hypoxia and subsequent recovery of the heart and pulmonary vasculature of the rat. Cardiovasc Res 5:95-102.
2. Aceto JF, Baker KM. 1990. [Sar1] angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol Heart Circ Physiol 258:H806-H813.
3. Akula A, Kota MK, Gopisetty SG, Chitrapu RV, Kalagara M, Kalagara S. 2003. Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats. Pharmacol Res 48:429-435.
4. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. 1983. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496-501.
5. Balabolkin MI, Klebanova EM, Kreminskaya VM. 1999. Angiopathia pathogenesis in diabetic patients. Sakharnyi diabet 2:2-9. [in Russian].
6. Balcells E, Meng QC, Johnson WH Jr., Oparil S, Dell'Italia LJ. 1997. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273:H1769-H1774.
7. Bancroft JD, Stevens A, editors. 1996. Theory and practice of histological techniques, 4th ed. New York, NY: Churchill Livingstone.
8. Baynes JW, Thorpe SR. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9.
9. Behl Y, Krothapalli P, Desta T, Roy S, Graves DT. 2009. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes 58:917-925.
10. Boudina S, Abel ED. 2007. Diabetic cardiomyopathy revisited. Circulation 115:3213-3223.
11. Butolin EG, Ivanov VG. 1998. Clinical informative value of biological fluids. Izhevsk: Ekspertisa. [in Russian].
12. Cagalinec M, Waczulikova I, Uličná O, Chorvat D Jr. 2013. Morphology and contractility of cardiac myocytes in early stages of streptozotocin-induced diabetes mellitus in rats. Physiol Res 62:489-501.
13. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. 2001. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973-1988.
14. Danilova IG, Gette IF. 2009. Alloxan diabetes mellitus modelling singularity. In Proceedings of Urgent problems of theoretical and applied biochemistry Conference on: 5-8 October 2009; Chelaybinsk. [in Russian].
15. Dedov II. 2003. Diabetes mellitus: angiopathia and oxidic stress: physicians' handbook. Moscow: Medichina. [in Russian].
16. Devereaux RB, Pickering TG, Cody RJ, Laragh JH. 1987. Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension. J Clin Hypertens 3:87-103.
17. Donath MY, Halban PA. 2004. Decreased β-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47:581-589.
18. Dorman JS, LaPorte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL. 1984. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. Diabetes 33:271-276.
19. Drews R, Meyer JU, Hahn W, Motz R, Hetzer R. 2004. Histomorphometric analysis of right ventricular myocardium in patients with diabetes mellitus. Pathol Res Pract 200:291.
20. Dyntar D, Sergeev P, Klisic J, Ambühl P, Schaub MC, Donath MY. 2006. High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation. J Clin Endocrinol Metab 91:1961-1967.
21. Egorov AM, Osipov, AP Dzantiyev BB, Gavrilova, EM. 1991. Theory and practice of immunoassay. Moscow: Vishaya Schkola. [in Russian].
22. Farmilo AJ, Stead RH. 2009. Fixation and processing. In: Kumar GL, Rudbeck L, editors. Immunohistochemical, staining methods. Carpinteria, CA: Dako North America. p 29-33.
23. Fein FS, Cho S, Zola BE, Miller B, Factor SM. 1989. Cardiac pathology in the hypertensive diabetic rat. Biventricular damage with right ventricular predominance. Am J Pathol 134:1159-1166.
24. Fein FS, Kornstein LB, Strobeck JE, Capasso JM, Sonnenblick EH. 1980. Altered myocardial mechanics in diabetic rats. Circ Res 47:922-933.
25. Feng B, Chen Sh, Chiu J, George B, Chakrabarti S. 2008. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 294:1119-1126.
26. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi P, Latini R. 2004. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37: 959-968.
27. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kajstura J. 2001. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50:2363-2375.
28. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J. 2000. Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 80:513-527.
29. Flecknell PA. 1987. Laboratory animal anaesthesia. An introduction for research workers and technicians. New York: Academic Press.
30. Friedman NE, Levitsky LL, Edidin DV, Vitullo DA, Lacina SJ, Chiemmongkoltip P. 1982. Echocardiographic evidence for impaired myocardial performance in children with type I diabetes mellitus. Am J Med 73:846-850.
31. Ghosh S, An D, Pulinilkunnil T, Qi D, Lau HC, Abrahani A, Innis SM, Rodrigues B. 2004a. Role of dietary fatty acids and acute hyperglycemia in modulating cardiac cell death. Nutrition 20:916-923.
32. Ghosh S, Ting S, Lau H, Pulinilkunnil T, An D, Qi D, Abrahani MA, Rodrigues B. 2004b. Increased efflux of glutathione conjugate in acutely diabetic cardiomyocytes. Can J Physiol Pharmacol 82: 879-887.
33. Giacco F, Brownlee M. 2010. Oxidative stress and diabetic complications. Circ Res 107:1058-1070.
34. Grigoleit HG, Lehrach F, Muller R. 1973. Diabetic angiopathy and blood viscosity. Acta Diabet Lat 10:1311-1324.
35. Grimm D, Jabusch HC, Kossmehl P, Huber M, Fredersdorf S, Griese DP, Krämer BK, Kromer EP. 2002. Experimental diabetes and left ventricular hypertrophy: effects of beta-receptor blockade. Cardiovasc Pathol 11:229-237.
36. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA. 1999. Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail 5:324-333.
37. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. 2003. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258-1264.
38. Institute of Laboratory Animal Resources (US). 1996. Guide for the care and used of laboratory animals. Washington: National Academies Press.
39. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R, Thienpont L, Umemoto M, Weykamp C. 2002. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 40:78-89.
40. Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP, Douglas PS. 1999. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with Doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 34:2111-2119.
41. Karamitsos TD, Karvounis HI, Dalamanga EG, Papadopoulos CE, Didangellos TP, Karamitsos DT, Parharidis GE, Louridas GE. 2007. Early diastolic impairment of diabetic heart: the significance of right ventricle. Int J Cardiol 114:218-223.
42. Karpischev AI, editor. 2002. Medical laboratory technology. St. Petersburg: Intermedika. [in Russian].
43. Katoh Y, Komuro I, Shibasaki Y, Yamaguchi H, Yazaki Y. 1989. Angiotensin II induces hypertrophy and oncogene expression in cultured rat heart myocytes (abstract). Circulation 80(Suppl II):II-450.
44. Kim S, Popel AS, Intaglietta M, Johnson PC. 2006. Effect of erythrocyte aggregation at normal human levels on functional capillary density in rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol 290:H941-H947.
45. Kita Y, Shimizu M, Sugihara N, Shimizu K, Yoshio H, Shibayama S, Takeda R. 1991. Correlation between histopathological changes and mechanical dysfunction in diabetic rat hearts. Diabetes Res Clin Pract 11:177-188.
46. Koenig H, Groat RA, Windle WF. 1945. A physiological approach to perfusion-flxation of tissues with formalin. Biotech Histochem 20:13-22.
47. Kosmala W, Przewlocka-Kosmala M, Mazurek W. 2007. Subclinical right ventricular dysfunction in diabetes mellitus: an ultrasonic strain/strain rate study. Diabet Med 24:656-663.
48. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. 1987. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750-755.
49. Kromer EP, Riegger GAJ. 1988. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 62:161-163.
50. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. 2003. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 46:760-765.
51. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. 1999. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 19:1014-1019.
52. Li P, Chen PM, Wang SW, Chen, LY. 2002. Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload. Hypertens Res 25:757-762.
53. Li Y, Ma J, Zhu H, Singh M, Hill D, Greer PA, Arnold JM, Abel ED, Peng T. 2011. Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 60:2985-2994.
54. Lie JT, Pairolero PC, Holley KE, Titus, JL. 1975. Macroscopic enzyme-mapping verification of large, homogeneous, experimental myocardial infarcts of predictable size and location in dogs. J Thorac Cardiovasc Surg 69:599.
55. Like AA, Rossini AA. 1976. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415-417.
56. Lillie RD. 1977. H.J. Conn's biological stains, 9th ed. Baltimore, MD: Williams and Wilkins.
57. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. 1996. Coronary artery disease in IDDM gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol 16:720-726.
58. Loreto D, Elina V. 2009. Experimental surgical models in the laboratory rat. Boca Raton: CRC Press.
59. Malaisse W. 1982. Alloxan toxicity to the pancreatic B-cell. Biochem Pharmacol 31:3527-3534.
60. Marcu CB, Beek AM, Vun Rossum AC. 2006. Cardiovascular magnetic resonance imaging for the assessment of right heart involvement in cardiac and pulmonary disease. Heart Lung Circ 15:362-370.
61. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. 2001. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 22:527-542.
62. Morrell NW, Danilov SM, Satyan KB, Morris KG, Stenmark KR. 1997. Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovasc Res 34:393-403.
63. Nathan DM. 1993. Long-term complications of diabetes mellitus. N Engl J Med 328:1676-1685.
64. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653.
65. Nemoto O, Kawaguchi M, Yaoita H, Miyake K, Maehara K, Maruyama Y. 2006. Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circ J 70:327-334.
66. Nørgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Deckert T. 1990. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33:407-410.
67. Nunoda SI, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. 1985. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1:43-47.
68. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KYZ, Kinder LS, Ellis D, Becker DJ. 2003. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diabetes Care 26:1374-1379.
69. Paisey RB, Harkness J, Hartog M, Chadwick T. 1980. The effect of improvement in diabetic control on plasma and whole blood viscosity. Diabetologia 19:345-349.
70. Poornima IG, Parikh P, Shannon RP. 2006. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98:596-605.
71. Prentø P. 1993. Van Gieson's picrofuchsin. The staining mechanisms for collagen and cytoplasm, and an examination of the dye diffusion rate model of differential staining. Histochemistry 99:163-174.
72. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916.
73. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. 1977. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60:884-899.
74. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. 1972. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595-602.
75. Sen S. 1983. Regression of cardiac hypertrophy: experimental animal model. Am J Med 75(Suppl 3A):87-93.
76. Serov RA, Chekareva GA, Raguzin KK, Shmureva TA. 1976. Staining with hematoxylin-basic fuchsin-picric acid (HBFP) for detection of myocardial lesions of different etiology. Arkhiv patologii 39:70-72.
77. Singh R, Barden A, Mori T, Beilin L. 2001. Advanced glycation end-products: a review. Diabetologia 44:129-146.
78. Singleton JR, Smith AG, Russell JW, Feldman EL. 2003. Microvascular complications of impaired glucose tolerance. Diabetes 52:2867-2873.
79. Stilli D, Lagrasta C, Berni R, Bocchi L, Savi M, Delucchi F, Graiani G, Monica M, Maestri R, Baruffi S, Rossi S, Macchi E, Musso E, Quaini, F. 2007. Preservation of ventricular performance at early stages of diabetic cardiomyopathy involves changes in myocyte size, number and intercellular coupling. Basic Res Cardiol 102:488-499.
80. Sun C, Munn LL. 2006. Influence of erythrocyte aggregation on leukocyte margination in postcapillary expansions: a lattice Boltzmann analysis. Physica A. 362:191-196.
81. Swindle MM, Adams RJ, editors. 1988. Experimental surgery and physiology: induced animal models of human disease. Baltimore, MD: Williams and Wilkins.
82. Szkudelski T. 2001. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:536-546.
83. Tijssen P. 1988. Laboratory techniques in biochemistry and molecular biology, practice and theory of enzyme immunoassays. Amsterdam: Elsevier.
84. Unger RH, Foster DW. 1998. Diabetes mellitus. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams textbook of endocrinology. Philadelphia, PA: WB Saunders Co. p 973-1059.
85. Wang J, Prakasa K, Bomma C, Tandri H, Dalal D, James C, Tichnell C, Corretti M, Bluemke D, Calkins H, Abraham TP. 2007. Comparison of novel echocardiographic parameters of right ventricular function with ejection fraction by cardiac magnetic resonance. J Am Soc Echocardiogr 20:1058-1064.
86. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. 1988. Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847.
87. Windebank A, Feldman E. 2001. Diabetes and the nervous system. In: Aminoff M, editor. Neurology and general medicine. Philadelphia, PA: Churchill Livingstone.
88. Yakovleva GE. 2005. The enzymes in clinical biochemistry. Novosibirsk: Vector-Best.
89. Yalcin O, Uyuklu M, Armstrong JK, Meiselman HJ, Baskurt OK. 2004. Graded alterations of RBC aggregation influence in vivo blood flow resistance. Am J Physiol Heart Circ Physiol 287:H2644-H2650.
90. Yamazaki T, Komuro I, Yazaki Y. 1998. Signalling pathways for cardiac hypertrophy. Cell Signal 10:693-698. doi: 10.1016/S0898-6568(98)00036-9.
91. Yamazaki T, Yazaki Y. 2000. Molecular basis of cardiac hypertrophy. Z Kardiol 89:1-6. doi: 10.1007/s00392005000.
92. Yu X, Tesiram Y, Towner R, Abbott A, Patterson E, Huang S, Garrett MW. 2007. Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc Diabetol 6:6. doi:10.1186/1475-2840-6-6.
93. Ze-Zhou S, Jing M. 2008. Early diastolic impairment of diabetic heart: the significance of right ventricle. Int J Cardiol 126:120-121.